Abstract
PR013 is a proprietary formulation of hypochlorous acid (HOCl) being developed for treatment of allergic conjunctivitis (AC). AC is induced by exposure to allergens resulting in hyperemia, inflammation, and pruritis. The goal of this study was to elucidate whether PR013 reduces hyperemia in an AC murine model and inhibits neuronal signaling in vitro.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
